orbitopathy

orbitopathy

 [or″bĭ-top´ah-the]
disease affecting the orbit and its contents.

or·bi·top·a·thy

(ōr'bi-top'ă-thē),
Disease of the orbit and its contents.

or·bi·top·a·thy

(ōr'bi-top'ă-thē)
Disease of the orbit and its contents.
References in periodicals archive ?
Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. Pediatr Endocrinol Rev, 2010;7:198-203.
Tear film profile in patients with active thyroid orbitopathy. Klin Oczna.
The body of clinical evidence with teprotumumab includes top-line positive results from the Phase 3 confirmatory clinical trial, called OPTIC (Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study), presented at the 2019 American Association of Clinical Endocrinologists (AACE) meeting, as well as positive Phase 2 results.
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
(3) Smoking is also a risk factor for the development of several ocular pathologies such as age-related macular degeneration, ischemic optic neuropathy, hypertensive retinopathy, cataract, glaucoma, thyroid orbitopathy, keratoconjunctivitis sicca, and strabismus in the offspring of smoking parents.
TED, also known as Graves' orbitopathy (GO), affects approximately 25% of patients with Graves' disease and is influenced by gender with females being more at risk (approximately 5:1).
The results of the current study, however, are contrary to results of Altiparmak et al., 2012, as their study suggested that cyclosporine 0.05% with artificial tears drops is not more advantageous than artificial tears alone for the dry eye patients of thyroid orbitopathy. The possible reason for these variations might be a different design, duration of the study and dose of cyclosporine and different the disease entity.
CT dimensions of the lacrimal gland in Graves orbitopathy. Ophthalmic Plast.
After hosting a call featuring an expert focused on thyroid eye disease, also known as Graves' orbitopathy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $25 price target.
Patients with IgG4-ROD often present with painless bilateral orbitopathy. The clinical symptoms are indolent and often occur as a result of regional mass effect or diffuse infiltration of involved tissues, including painless proptosis, diplopia, and impaired eye movements (40).